Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects.

Dénes CsonkaShirin BrudererArmin SchultzMarianne SoergelRadka StepanovaGiancarlo SabattiniJuan Jose Perez-Ruixo

Published in: Clinical drug investigation (2020)

Macitentan 10 mg did not affect the pharmacokinetics of BCRP substrates, rosuvastatin or riociguat in healthy male subjects. EudraCT numbers: 2017-003095-31 and 2017-003502-41.

Keyphrases

pulmonary hypertension
pulmonary arterial hypertension
binding protein
small molecule